TherOx(TM) AMIHOT II Pivotal Trial Meets Endpoints.

Data Shows Significant Infarct Size Reduction in Acute Myocardial Infarction Patients

WASHINGTON -- TherOx, Inc., a privately held medical device company, announced it has successfully met its endpoints for its pivotal trial, AMIHOT II (Acute Myocardial Infarction with Hyperoxemic Oxygen Therapy), which studied SuperOxygenation Therapy for Acute Myocardial Infarction (AMI) patients. The results were presented today during a late-breaking session at the 19th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in Washington D.C. The data will be submitted shortly to the FDA as part of the company's Premarket Approval (PMA) application.

AMIHOT II showed superiority of the adjunctive administration of SuperOxygenation Therapy over the current AMI standard of care alone - available drug regimens coupled with urgent Percutaneous Coronary Intervention (PCI) - by demonstrating a significant reduction in infarct size for patients treated within six hours from symptom onset for anterior AMI. The prospective, multi-center, randomized trial studied more than 300 STEMI (ST-segment Elevation Myocardial Infarction) patients for a new therapy called SuperOxygenation Therapy, in a new treatment category called Myocardial Salvage Intervention (MSI).

SuperOxygenation Therapy, an adjunctive therapy performed immediately after PCI, is the first and only treatment option post-PCI that has shown promise to reduce infarct size and thus preserve heart muscle during an acute heart attack. Myocardial Salvage Intervention is a new treatment category for AMI patients that salvages the jeopardized myocardium and reduces infarct size.

"AMIHOT II demonstrated a significant reduction in infarct size with SuperOxygenation Therapy compared to the current standard of care for anterior AMI patients treated by angioplasty within six hours of symptom onset," said the study's principal investigator, Dr. Gregg W. Stone from Columbia University Medical Center and the Cardiovascular Research Foundation in New York. "The positive results shown in AMIHOT II significantly expand AMI treatment options for interventional cardiologists and their patients affected by large heart attacks."

SuperOxygenation Therapy intends to provide a solution for many of the 1.2 million Americans who have acute heart attacks each year.

"With the positive results of our clinical trial, we have made a significant step towards providing a treatment option that addresses Myocardial Salvage Intervention for a large group of heart attack patients," said Kevin Larkin, president and CEO of TherOx. "SuperOxygenation Therapy is poised to have a major impact on the industry. Reducing infarct size has been shown to improve heart function and patient outcomes including mortality and quality of life."

About TherOx

TherOx, a privately held medical device company based in Irvine, Calif., is focused on developing and commercializing its SuperOxygenation Therapy to save hearts, to ultimately save lives. Its therapy is the first and only treatment option post-percutaneous coronary intervention that salvages heart muscle in acute heart attack patients. SuperOxygenation Therapy will provide interventional cardiologists with the first treatment option that addresses Myocardial Salvage Intervention for acute heart attack patients. For more information, visit www.therox.com.

Caution: Investigational device. Limited by Federal (or United States) law to investigational use.